期刊文献+

草酸铂与Cl^-的取代反应动力学 被引量:2

Kinetics of the Substitution Reactions of Oxaliplatin and Cl^-
下载PDF
导出
摘要 采用高效液相色谱研究了新型铂类抗癌药草酸铂与Cl-的取代反应动力学,并讨论了酸性条件下H+对取代反应的影响。结果表明,Cl-大量存在时,体系中草酸铂与Cl-的取代反应为优势反应,反应对草酸铂和Cl-均为一级。根据动力学数据提出了可能的反应机理,并由此推导出反应速率r=(KClk5'+K1'k3)犤L-OHP犦犤Cl-犦,与实验结果相吻合;当H+也大量存在时,取代反应被加速,此时表观速率常数kobs与犤H+犦、犤Cl-犦之间呈非线性递增,但反应对草酸铂仍为一级。在生理盐水中,反应的准一级速率常数kobs=3.6×10-4min-1,1%~2%的草酸铂发生反应所需时间不足1h,因此临床使用草酸铂时要避免与Cl-配伍。 The substitution reactions of oxaliplatin with Cl^- have been studied by high performance liquid chromatograph in neutral and acid aqueous solution.The experimental results show that under the condition ofCl - 0L-OHP 0 the reactions of oxaliplatin with Cl - are first order in both oxaliplatin a nd Cl - ,which have advantage over other reactions.In this paper,the p ossible mechanism has been proposed.From it,the rate law r=(K Cl k 5 ' +K 1 ' k 3 )Cl - L-OHPis deduced,which is in perfect agreement with the experiment results.Wh en excess acid is added to the systems,the reactions o f oxaliplatin with Cl - are accelerated by H + and the observed rate constants k obs are nonlinearly increased with the i mprovement ofH +orCl -.However,the rates of the reactions still follow to the first order dependence on L-OHP.In 0.9%NaCl solution,the pseu do-first-order rate constant k obs is3.6×10 -4 min -1 ,which determines that it takes less one hour for 1%~2%of oxaliplatin reacting with Cl - .As a result,the physiological saline so lution should not be used to dissolve or dilute the complex in clinical.
出处 《无机化学学报》 SCIE CAS CSCD 北大核心 2002年第7期679-682,共4页 Chinese Journal of Inorganic Chemistry
关键词 动力学 草酸铂 取代反应 准一级反应 表观速率常数 氯离子 铂类抗癌药物 oxaliplatin substitutio n reaction pseudo-first-order reaction observed rate constant
  • 相关文献

参考文献4

  • 1XU Qing(许青)Guowai Yiyao(World Pharmacy),2000,21(2),99. 被引量:1
  • 2SUN Yan(孙燕),GUAN Zhong-Zhen(管忠震),JIN MaoLin(金懋林).Li Wei-Lian(李维廉)Aizheng(Chinese J.of Cancer),1999,18(3),237. 被引量:1
  • 3LIU Zhu-Dong(刘祝东),PU Shao-Ping(普绍平),GAO Wen-Gui(高文桂),YU Yao(余尧)Youse Jinshu( Noferrous Metals), 2002, 54, suppl.,355. 被引量:1
  • 4Heudi O., Mereier-Jobard S., Cailleux A. et al Biopharm.Drug Dispos., 1999, 20(2), 107. 被引量:1

同被引文献11

  • 1Meyers PA, Godick R, HeUer G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma., results of the memorial sloan-kettering (T12) protocol [J]. J Clin On col, 1998, 16 (7).. 2452-2458. 被引量:1
  • 2J. W. NiaL, W. Shonagh, E. G. Gemma, et al. The status of platinum anticancer drugs in the clinic and clinical trials.[J]. DaLton Trans, 2010, 39, 8113-8127. 被引量:1
  • 3L. KeLLand. Resurgence of pLatinum based cancer chemo- therapy [J]. Nat. Rev. Cancer , 2007, 7: 573-584. 被引量:1
  • 4C. A. Rabic, M. E. DoLan. MoLecuLar mechanisms of re- sistance and toxicity associated with pLatinating agents [J]. Cancer Treat. Rev, 2007, 33: 9-23. 被引量:1
  • 5金宜纫,黄天木.卡铂的稳定性研究[J].中国医院工业杂志,1994,2:69-72. 被引量:1
  • 6A. S. Abu-Surrah, M. Kettunen. PLatinum group antitumor chemistry [J]. Curr. Med. Chem, 2006, 13: 1337-1357. 被引量:1
  • 7Komeda S, Casini A. Next-generation anticancer metallo- drugs[J]. Curr Top Med Chem, 2012, 12(3): 219-235. 被引量:1
  • 8Potucka L, Houskova J, Syslova K, et al. HPLC method for the determination of the purity of K[Pt(NH3)C13], a precursor of the platinum complexes with cytostatic activity[J]. Anal Lett, 2011, 44(12): 2182-2193. 被引量:1
  • 9普绍平,丛艳伟,王庆琨,贝玉祥,栾春芳,李学杰,孙加林.甲啶铂的合成、表征、理化性质与晶体结构[J].中国新药杂志,2010,19(17):1605-1608. 被引量:6
  • 10王庆琨,普绍平,何键,刘凉萌,廖云星,晋杰.抗肿瘤新药甲啶铂的合成工艺研究[J].贵金属,2013,34(4):37-39. 被引量:3

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部